Abrams Capital Management NUVB trades
David Abrams
David Abrams Nuvation Bio Inc stake
total: 84
Trades details
- Total transactions:
- 2
- New positions:
- 1
- Reduced:
- 1
- Held since:
- 2021 Q1
- Held for:
- 22 quarters
- Latest activity:
- 2026 Q1
According to 2026 Q2 report, David Abrams holds 1,270,504 Nuvation Bio Inc (NUVB) shares with a market value of roughly $7.22M accounting for 0.13% of the overall portfolio. To date, the estimated cost basis is nearly $8.92 for "buy" trades and estimated average "sell" price is $4.29. Abrams Capital Management first purchased NUVB in 2021 Q1, initially acquiring about 3.81M shares. Since the initial investment in Nuvation Bio Inc (NUVB), Abrams Capital Management has made 1 more transaction.
When did David Abrams buy Nuvation Bio Inc (NUVB)?
David Abrams first invested in Nuvation Bio Inc (NUVB) in 2021 Q1 at the reported quarter-end price of $8.92 per share.
What's the cost basis of Abrams Capital Management's NUVB stake?
The estimated cost basis for Nuvation Bio Inc (NUVB) stake is around $8.92 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $8.92
- Weighted AVG sell price:
- $4.29
David Abrams's historical trades in Nuvation Bio Inc
2 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
0.12%
|
1,270,504
|
$4.29
|
$5,450,462
|
-66.67% (-2,541,009)
|
-0.19%
|
|
2021 Q1
|
0.77%
|
3,811,513
|
$8.92
|
$33,989,000
|
new
|
+0.77%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.